Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
dc.contributor.author | Plummer, R | |
dc.contributor.author | Cook, Natalie | |
dc.contributor.author | Arkenau, T | |
dc.contributor.author | Melear, J | |
dc.contributor.author | Redfern, C | |
dc.contributor.author | Spira, A | |
dc.contributor.author | Chung, K | |
dc.contributor.author | Haddad, T | |
dc.contributor.author | Ramalingam, S | |
dc.contributor.author | Wesolowski, R | |
dc.contributor.author | Dean, Emma J | |
dc.contributor.author | Goddemeier, T | |
dc.contributor.author | Falk, M | |
dc.contributor.author | Shapiro, G | |
dc.date.accessioned | 2019-04-29T09:49:02Z | |
dc.date.available | 2019-04-29T09:49:02Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Plummer R, Cook N, Arkenau T, Melear J, Redfern C, Spira AI, et al. 1437P Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl_8):519. | en |
dc.identifier.doi | 10.1093/annonc/mdy292.059 | en |
dc.identifier.uri | http://hdl.handle.net/10541/621813 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdy292.059 | en |
dc.title | Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Northern Centre for Cancer Care, Freeman Hospital, Newcastle Upon Tyne, UK | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-04-20T12:02:11Z |